GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Ablynx Achieves First Milestone With P&GP

  • Ablynx reached a first milestone in its discovery and development collaboration with Procter & Gamble Pharmaceuticals (P&GP) establishing the potential of Ablynx’ Nanobody® technology for possible new treatments in the musculoskeletal category.

    The Nanobody® technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies® against one of the targets exclusive to the collaboration, triggering a milestone payment. 

    As part of this on-going collaboration Ablynx is responsible for discovering Nanobodies® that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies® as well as the commercialization of any resulting drug products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?